• Fourth clinical trial opened with monalizumab (IPH2201)

    December 17, 2015
    Phase Ib/II trial testing monalizumab in combination with cetuximab in patients with relapsed or refractory head and neck cancer Trial conducted in Europe and the United States Innate Pharma SA (the...
  • First patient dosed in Phase I trial of IPH4102

    December 3, 2015
    Proprietary, new cytotoxic anti-KIR3DL2 monoclonal antibody in development for the treatment of cutaneous T-cell lymphoma (CTCL); Orphan drug designation in the European Union; Innate’s third first-...
  • New combination trial with lirilumab in hemato-oncology

    November 12, 2015
    8 trials ongoing with lirilumab in multiple indications and combinations 5 combination trials ongoing in hemato-oncology Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH)...
  • Third Quarter 2015 Report

    November 5, 2015
    Cash, cash equivalents and financial instruments amounting to €270 million ; US$5 million milestone payment received from Bristol-Myers Squibb for the initiation of a new Phase II trial in hemato-...